Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Open Access
- 1 January 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (1), 58-63
- https://doi.org/10.1001/archneurol.2009.294
Abstract
Drugs that increase mesocorticolimbic dopamine, such as cocaine and amphetamines, produce physical and psychological dependence (addiction) and stereotyped withdrawal syndromes after prolonged, heavy use. Withdrawal syndromes are substance specific and commonly include anxiety, panic attacks, dysphoria, irritability, agitation, pain, sleep disturbance, fatigue, orthostatic hypotension, diaphoresis, and drug cravings. These symptoms cause significant distress or impairment in social/occupational functioning and can lead to suicidality.1This publication has 23 references indexed in Scilit:
- Is depression associated with dysfunction of the central reward system?Biochemical Society Transactions, 2009
- Dopamine and impulse control disorders in Parkinson's diseaseAnnals of Neurology, 2009
- Impulse Control and Related Disorders in Parkinson's DiseaseAnnals of the New York Academy of Sciences, 2008
- A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's diseaseBrain, 2008
- Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Drug Insight: impulse control disorders and dopamine therapies in Parkinson's diseaseNature Clinical Practice Neurology, 2007
- Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta‐analysis of ten years' experienceMovement Disorders, 2007
- Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson DiseaseArchives of Neurology, 2006
- Pathological gambling is linked to reduced activation of the mesolimbic reward systemNature Neuroscience, 2005
- Disabling repetitive behaviors in Parkinson's diseaseMovement Disorders, 2003